Enhanced nuclear export caused by O-GlcNAcylation of nucleoporins is a potential therapeutic target in mesothelioma

May 7, 2026 | Comments Off on Enhanced nuclear export caused by O-GlcNAcylation of nucleoporins is a potential therapeutic target in mesothelioma

British Journal of Cancer 2026 May [Link] Satomi Mukai, Tatsuhiro Sato, Yasuhiro Kamei, Kagayaki Kato, Emi Mishiro-Sato, Lisa Kondo-Ida, Norikazu Yabuta, Kenzo Hiroshima, Yoshitaka Sekido Abstract Background: Mesothelioma is an…

Advancing Rare Cancer Therapeutics: Osimertinib-Loaded Inhaled PLGA Nanoparticles for Mesothelioma Treatment

May 6, 2026 | Comments Off on Advancing Rare Cancer Therapeutics: Osimertinib-Loaded Inhaled PLGA Nanoparticles for Mesothelioma Treatment

AAPS PharmSciTech 2026 March 4 [Link] Mural Quadros, Naveen Rajana, Vivek Gupta Abstract Despite advances in mesothelioma treatment, malignant pleural mesothelioma (MPM) continues to present a poor prognosis due to…

Effects of Autophagy Inhibition by SAR405, a Selective VPS34 Inhibitor, on Pleural Mesothelioma Cells

May 5, 2026 | Comments Off on Effects of Autophagy Inhibition by SAR405, a Selective VPS34 Inhibitor, on Pleural Mesothelioma Cells

Thoracic Cancer 2026 March [Link] Yoshiki Kuwabara, Kosuke Sakai, Kota Shiraishi, Itsuka Matsumoto, Shigeru Ishii, Shin Yokosuka, Masatoshi Abe, Tomoyuki Takahashi, Yuichiro Kawano, Hiroaki Nishimura, Maiko Toda-Sasaki, Yumiko Kobayashi-Ogawa, Satoshi…

Medical thoracoscopy with talc poudrage and indwelling pleural catheter insertion versus medical thoracoscopy with talc poudrage alone for patients with symptomatic malignant pleural effusion (TACTIC): a randomised, controlled phase 3 trial

May 4, 2026 | Comments Off on Medical thoracoscopy with talc poudrage and indwelling pleural catheter insertion versus medical thoracoscopy with talc poudrage alone for patients with symptomatic malignant pleural effusion (TACTIC): a randomised, controlled phase 3 trial

The Lancet. Respiratory Medicine 2026 April [Link] Alexandra Dipper, Anand Sundaralingam, Emma Hedley, Sharada Gudur, Janet Mills, Sandra Sowden, John P Corcoran, Cyrus Daneshvar, Chris Craig, Andrew J Moore, Alice…

Targeting fatty acid synthase suppresses tumor development in NF2/CDKN2A-deficient pleural mesothelioma

May 1, 2026 | Comments Off on Targeting fatty acid synthase suppresses tumor development in NF2/CDKN2A-deficient pleural mesothelioma

Cell Death & Disease 2026 February 28 [Link] Sivasundaram Karnan, Akinobu Ota, Muhammad Nazmul Hasan, Hideki Murakami, Md Lutfur Rahman, Md Wahiduzzaman, Md Towhid Ahmed Shihan, Nushrat Jahan, Lam Quang…

Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: Efficacy, Real-World Outcomes, and the Search for Predictive Biomarkers

April 30, 2026 | Comments Off on Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: Efficacy, Real-World Outcomes, and the Search for Predictive Biomarkers

Current Oncology 2026 February 3 [Link] Giusi Bondì, Serafina Martella, Dimitrios Stylianakis, Alberto Terminella, Filippo Lococo, Alessia Ciarrocchi, Alfonso Fiorelli, Giacomo Cusumano Abstract Immunotherapy has significantly reshaped the management of…

Clinical Importance of Molecular Biomarkers in Pleural Mesothelioma

April 29, 2026 | Comments Off on Clinical Importance of Molecular Biomarkers in Pleural Mesothelioma

Cancers 2026 February 19 [Link] Logan Roof, Kenna Koehler, Claire Verschraegen Abstract Pleural mesothelioma (PM) is a rare malignancy with opportunities for improvement in current treatment paradigms despite recent advances…

Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743

April 28, 2026 | Comments Off on Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743

Journal of Clinical Oncology 2026 March 20 [Link] Arnaud Scherpereel, Paul Baas, Anna K Nowak, Anne S Tsao, Nobukazu Fujimoto, Solange Peters, Aaron S Mansfield, Sanjay Popat, Yolanda Bautista Aragon,…

Mesothelioma location influences the tumour microenvironment and immune checkpoint therapy response in preclinical models

April 27, 2026 | Comments Off on Mesothelioma location influences the tumour microenvironment and immune checkpoint therapy response in preclinical models

Scientific Reports 2026 February 25 [Link] M Lizeth Orozco Morales, Sally M Lansley, Wee Loong Chin, Caitlin M Tilsed, Nicola Principe, Connull Leslie, Breana J Vitali, Francois X Rwandamuriye, Emma…

Mesothelioma location influences the tumour microenvironment and immune checkpoint therapy response in preclinical models

April 24, 2026 | Comments Off on Mesothelioma location influences the tumour microenvironment and immune checkpoint therapy response in preclinical models

Scientific Reports 2026 February 25 [Link] M Lizeth Orozco Morales, Sally M Lansley, Wee Loong Chin, Caitlin M Tilsed, Nicola Principe, Connull Leslie, Breana J Vitali, Francois X Rwandamuriye, Emma…

Categories